Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 157

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 157
---
 Canada, Russia, Mexico, Singapore, and India. These patents or patents
issuing from these pending applications will begin to expire in 2039, exclusive of possible patent term adjustments or extensions or other
forms of exclusivity.

We have 15 issued patents,
and 16 pending patent applications, relating to a number of our applicators and other accessories that are used in the Alpha DaRT source
itself or in its delivery. The 15 issued patents have been issued in the U. S., Korea, South Africa, India, China, and Hong Kong, Russia
and Australia. The 16 patent applications are pending in the U. S., Europe, Japan, Canada, China, Korea, ARIPO, Mexico, Hong Kong, Singapore,
South Africa and Australia. These patents or patents issuing from these pending applications will begin to expire in 2039, exclusive of
possible patent term adjustments or extensions or other forms of exclusivity.

We have four issued patents,
and nine pending patent applications, relating to a therapeutic substance administered to a tumor as a medicant, which triggers cytoplasmatic
sensors to the presence of an intracellular pathogen, followed by intratumoral Alpha DaRT thereafter. The four issued patents have been
issued in China, Australia, Russia and Hong Kong. The nine patent applications are pending in the U. S., Europe, Japan, China, Canada,
Australia, Korea, Singapore and Hong Kong. These patents or patents issuing from these patent applications begin to expire in 2039, exclusive
of possible patent term adjustments or extensions or other forms of exclusivity.

We have nine issued patents,
and 12 pending patent applications, including one allowed patent, relating to our newer liquid method of radium production, as described
above. The nine issued patents have been issued in Japan, Australia, South Africa, Singapore, and Russia. The 12 patent applications are
pending in the U. S., Europe, Japan, China, Hong Kong, Mexico, Singapore, ARIPO, Korea, Canada and India, of which one Japan patent application
has been allowed. These patents or patents issuing from these pending applications will begin to expire in 2040, exclusive of possible
patent term adjustments or extensions or other forms of exclusivity.

We
have two issued patents and 16 pending patent applications relating to tailored amounts of radioactivity levels to a tumor in a radiotherapy
treatment. The two issued patents have been issued in the U. S. and Australia